This study aimed to examine the performance of two algorithms for diagnosis of hypertensive disorders of pregnancy (HDP) with medical record data from a large cohort of pregnant women. In this article, the researchers emphasize the importance of having an accurate method of identifying HDP in large-scale studies, given the potential health implications for pregnant women.
The algorithms tested in this study were based on American and Japanese guidelines and tested on data from nearly 23,000 pregnant women in Japan’s BirThree Cohort Study. These algorithms considered various factors such as blood pressure levels, previous high blood pressure history, protein in the urine (proteinuria), and signs of maternal organ dysfunction to diagnose conditions like gestational hypertension, early and late-onset preeclampsia, and early and late-onset superimposed preeclampsia.
Overall applying these algorithms to the data, researchers were able to accurately identify HDP diagnoses and their sub-types in this research cohort. The positive predictive value (PPV) is a statistical metric used to measure the algorithms' performance. The PPV indicated the proportion of actual positive diagnoses (true HDP cases) among all positive results given by the algorithms. The PPVs were 96% and 90% for the American and Japanese algorithms, respectively. This high accuracy demonstrates the reliability of using these diagnostic tools in large cohort studies to identify different types of hypertensive disorders during pregnancy.
Take Home Message: This study demonstrates that applying these algorithms to large cohort data of pregnant individuals can help identify HDP and therefore be used to support HDP research.
Link: https://www.nature.com/articles/s41598-024-55914-9
Citation: Mizuno, S., Wagata, M., Nagaie, S., Ishikuro, M., Obara, T., Tamiya, G., Kuriyama, S., Tanaka, H., Yaegashi, N., Yamamoto, M., Sugawara, J., & Ogishima, S. (2024, March 15). Development of phenotyping algorithms for hypertensive disorders of pregnancy (HDP) and their application in more than 22,000 pregnant women. Nature News. https://www.nature.com/articles/s41598-024-55914-9
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
Preeclampsia is a major cause of maternal and fetal morbidity and mortality. Prompt and accurate diagnosis is necessary to prevent adverse outcomes. A study was completed to determine the accura...
Predicting preeclampsia has proven to be a challenge. Researchers have documented many differences in early pregnancy between those who eventually develop preeclampsia and those who do not. These incl...
The U.S. Preventive Services Task Force (USPSTF) and American College of Obstetricians and Gynecologists (ACOG) guidelines changed in 2021 to help prevent preeclampsia. Low-dose aspirin has been shown...
Hypertensive disorders of pregnancy (HDP), including preeclampsia, affect 1 in 6 pregnancies. HDP is a general term for a range of mild to severe outcomes. Until now there has not been a reliabl...
Although there is no definitive treatment for preeclampsia, early screening and detection can allow patients to ensure proper management throughout the remainder of the pregnancy. Currently, preeclam...